CARsgen Announces Positive Topline Results from China GC/GEJ Pivotal Phase II Clinical Trial of Claudin18.2 CAR-T (Satri-cel)

CARsgen’s Allogeneic CAR-T Product Developed on the THANK-u Plus Platform Administers First Dose in an IIT

CARsgen^® to Present Zevor-cel, CT071 and CT0590 at ASH 2024 Annual Congress

CARsgen^® U.S. Clinical Holds Lifted by FDA

CARsgen^® Submitted Application to Request Lifting Clinical Holds to FDA

CARsgen^® Announces 2024 Interim Results

CARsgen Announces Enrollment Completion in China GC/GEJ Pivotal Phase II Clinical Trial of the First-in-class Claudin18.2 CAR T (Satri-cel)

CARsgen Presents Phase II Results on Zevorcabtagene Autoleucel and First-in-human CT071 Results at EHA 2024

CARsgen Presents First-in-human Results of GPRC5D Targeting CAR-T CT071 at EHA 2024

CARsgen Presents Updated Results on Satri-cel in Nature Medicine and at 2024 ASCO